36 results about "Amphotericin B" patented technology

Provided are an amphotericin B amide derivative and a use thereof. The amphotericin B amide derivative is as shown in formula (I). The compound has good antifungal activity, is effective against various fungi, has good water solubility, is adapted to be developed into an injection dosage form, has excellent metabolic stability in animals (such as mice, rats, dogs, and monkeys), has a long half-life period, can effectively reduce the frequency of administration, has weak inhibition on CYP enzymes, and has a low risk of drug interaction.

The invention provides an amphotericin B amide derivative and application thereof. The amphotericin B amide derivative is shown as a formula (I), has good antifungal activity, is effective to various fungi, has good water solubility, is suitable for being developed into injections, has excellent metabolic stability in animal bodies (such as mice, rats, dogs and monkeys), is long in half-life period, can effectively reduce the administration frequency, is weak in CYP enzyme inhibition, and can be used for preparing the antifungal drugs. The drug interaction risk is low.

The invention relates to a process for obtaining an amphotericin B (AmB) formulation in liposomes containing dicetyl phosphate (DCP), based on incorporation of the drug into the membrane of preformed liposomes, combining the effects of pH on the solubility of amphotericin B and of temperature on the insertion of the drug into the liposome membrane. The technology also relates to use of the process and of the formulation for the manufacture of medicaments for the treatment of leishmaniasis and sporotrichosis, for oral or topical administration.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

Provided are a combination of an inositol phosphorylceramide synthase inhibitor and amphotericin B and use thereof. The use includes preparing a pharmaceutical composition, which includes an inositol phosphorylceramide synthetase inhibitor and amphotericin B or a salt thereof. Inositol phosphorylceramide is an important and conserved component of fungal plasma membranes. In the pharmaceutical composition according to an embodiment of the present disclosure, due to the presence of the inositol phosphorylceramide synthase inhibitor, the interaction between the inositol phosphorylceramide synthase inhibitor and amphotericin B not only enhances the inhibitory ability of the inositol phosphorylceramide synthase inhibitor on the synthesis of inositol phosphorylceramide in Cryptococcus, but also effectively reduces the dosage of amphotericin B and prolongs the half-life of amphotericin B, facilitating to reduce the adverse reactions of amphotericin B. The pharmaceutical composition exhibits superior fungicidal effect and safety compared to the currently used clinical combination of 5-fluorocytosine and amphotericin B.

Disclosed is a simplified, readily scalable series of individual methods that collectively constitute a method for the synthesis of C2'epiAmB, an efficacious and reduced-toxicity derivative of amphotericin B (AmB), beginning from AmB. Also provided are various compounds corresponding to intermediates in accordance with the series of methods.

The present application relates to the use of amphotericin B or its combination in the preparation of anti-tumor drugs. The present application first confirms that amphotericin B directly binds to Toll-like receptor 2 and activates the downstream signaling pathway as a Toll-like receptor 2 agonist, thereby enhancing the phagocytic ability of macrophages to tumor cells; it is first confirmed that amphotericin B combined with therapeutic antibodies can produce a synergistic anti-tumor effect, and the above synergistic effect is mainly due to the regulatory effect of amphotericin B on macrophage function, including enhancing Fc gamma receptor expression and polarizing macrophages to M1 direction, which provides a solid foundation for the clinical transformation of amphotericin B and is expected to provide new treatment options for cancer patients.

This application relates to the field of biotechnology, and particularly to primer pairs, primer-probe compositions, PCR premixes, kits, and methods for detecting multiple respiratory pathogens. Nucleic acid sequences are shown in primer pairs as indicated by SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38, and 40-41. For target respiratory pathogens, this application designs specific amplification primer pairs, paired with suitable probes, enabling the simultaneous detection of eight targets. Furthermore, the detection process avoids interference from heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, adrenaline, and lidocaine hydrochloride in the test sample. It exhibits good anti-interference properties and shows no cross-reactivity with *Rhodococcus equi*, *Candida tropicalis*, and *Candida krusei*.

This invention belongs to the field of organoid culture technology, specifically relating to a highly efficient organoid anticontamination reagent. This highly efficient organoid anticontamination reagent is composed of Primocin, amphotericin B, and Y-27632. In the organoid culture medium system, the final concentration of Primocin is 20-70 μg / mL, the final concentration of amphotericin B is 0.1-1 μg / mL, and the final concentration of Y-27632 is 5-20 μM. The highly efficient organoid anticontamination reagent provided by this invention exhibits dual high-efficiency inhibition against both bacteria and fungi, has a broad anticontamination spectrum, and is not prone to inducing microbial resistance. Simultaneously, it can reduce cytotoxicity, and long-term use does not alter the expression of organoid-specific markers, thus maintaining differentiation function.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The invention provides an amphotericin B hydrazide derivative and application thereof. The amphotericin B hydrazide derivative is shown as a formula (I). The compound disclosed by the invention has an obvious inhibition effect on the growth of candida albicans, aspergillus fumigatus and aspergillus flavus. (I).

Disclosed are therapeutic methods for treating a disease or condition characterized by decreased expression or reduced function of an ion channel using an amphotericin B derivative, or an amphotericin B derivative and an ion channel modulator. The methods can be used to treat cystic fibrosis.

The application discloses a kind of Vibration Mountain beard toad hind leg / toe tissue cells and its quick acquisition method and application.The method comprises: the body surface disinfection of Vibration Mountain beard individual, cut and take hind leg or toe tissue, and put back after wound disinfection;After tissue is soaked in 75% alcohol and washed with PBS containing penicillin, streptomycin and amphotericin B, it is temporarily stored in 4 ℃ temporary storage solution;After tissue is cut, it is sequentially digested with trypsin and type I collagenase;In the optimized low permeability medium, primary culture is carried out at 25-27 ℃;When cell confluence reaches 60%-70%, it is passaged using trypsin-EDTA digestion;Freezing and recovery.The application realizes the non-lethal cell of Vibration Mountain beard for the first time Quick acquisition, cell first time migration time is only 3 days, grow into monolayer only 12-17 days, pollution rate is reduced to 5.6%, recovery survival rate reaches 76.19%, and provides efficient and reliable technical support for endangered amphibian germplasm resource preservation and biological research.

The invention provides application of combined use of amphotericin B and sorafenib in preparation of a medicine for treating liver cancer. The invention also provides a pharmaceutical composition for treating liver cancer. The pharmaceutical composition is prepared from the following raw material medicines in parts by mass: 1-3 parts of amphotericin B and 1-10 parts of sorafenib. Pharmacodynamic tests prove that the amphotericin B and the sorafenib are combined to be used for treating the liver cancer, and the synergistic interaction effect is achieved.

Disclosed are pharmaceutical compositions, comprising: (i) amphotericin B or a pharmaceutically acceptable salt or hydrate thereof; (ii) cholesterol; (iii) phospholipids, comprising hydrogenated soy phosphatidylcholine and distearoylphosphatidylglycerol; and (iv) calcium chloride (CaCl2). Also disclosed are methods of using the pharmaceutical compositions for treating a disease or disorder (e.g., cystic fibrosis), increasing the pH of airway surface liquid, increasing bicarbonate secretion into airway surface liquid, and increasing a subject's forced expiratory volume in one second.

The present invention provides a quaternary ammonium salt derivative of amphotericin B and a use thereof. The quaternary ammonium salt derivative of amphotericin B is as shown in formula (I), has good antifungal activity, is effective against various fungi, has good water solubility, is suitable for development into an injection dosage form, has excellent metabolic stability in animals and long half-life, can effectively reduce the frequency of administration, has weak inhibition on CYP enzymes, and has low risk of drug interaction.

The application discloses use of Amphotericin B in preparation of a medicine for preventing and / or treating ASFV infection, and belongs to the technical field of biotechnology. During the research, it is accidentally found that adding the compound Amphotericin B into a culture medium for culturing ASFV can reduce the replication level of the ASFV, indicating that the compound Amphotericin B has an effect of inhibiting the replication of the ASFV, and can be used for preparing a medicine or an adjuvant against the ASFV infection, and can be applied to inhibiting the replication of the ASFV, and has a wide application prospect.

The invention relates to the technical field of tissue engineering, and particularly discloses a pilose antler tissue cell culture method which comprises the following steps: S1, cell in-vitro culture; s2, directional induced differentiation; step S3, ossification induction; the induction culture medium 1, the induction culture medium 2 and the ossification induction culture medium are added, amphotericin B capable of covering the fungal pollution risk is added into the induction culture medium 1, fetal calf serum contained in the induction culture medium 1 can neutralize trypsin, recombinant human HGF contained in the induction culture medium 2 can improve the migration ability of cells, and meanwhile, the ossification induction culture medium can be used for preparing the ossification culture medium. The recombinant human bFGF can synergistically promote proliferation, so that emigrated cells are quickly accumulated, and the situation that the cell density is too low due to insufficient proliferation after emigration is avoided; ascorbic acid-2-phosphate contained in the ossification induction culture medium can avoid oxidation failure of ascorbic acid, and the cell emigration efficiency is improved through the synergistic effect of the substances.

This invention provides an electrospun gastric perforation patch based on Ag / Zn bimetallic MOF and its preparation method. The gastric perforation patch comprises a tissue integration layer, an antibacterial drug-loaded core layer, and an anti-adhesion layer integrally formed by electrospinning. The antibacterial drug-loaded core layer is composed of Ag / Zn bimetallic MOF loaded with antifungal drugs and a biodegradable polymer material. In the Ag / Zn bimetallic MOF, the molar ratio of zinc to silver is (8:1) to (12:1), and the antifungal drug is voriconazole or amphotericin B. This invention combines the broad-spectrum antimicrobial properties of Ag / Zn bimetallic MOF with a three-layer functional gradient design, enabling the patch to adhere firmly to tissue without sutures. It can actively prevent infection, inhibit adhesion, promote tissue regeneration, and gradually degrade and absorb postoperatively, significantly reducing the risk of foreign body reaction, infection, and recurrence, demonstrating excellent biocompatibility and broad clinical application prospects.

The invention belongs to the field of pharmaceutical preparations. The invention relates to a preparation method and application of probiotic coupled hyaluronic acid / chitosan oligosaccharide modified paclitaxel, amphotericin B and high-entropy nano-enzyme lipid nanoparticles. The prepared probiotic coupled lipid nanoparticles are good in biocompatibility, the preparation method is simple, the particle size distribution of the nanoparticles is uniform, chemotherapeutic drugs can be selectively enriched in tumor tissues, the treatment effect on cancers is remarkably enhanced by cooperating with a chemical kinetics therapy, and the probiotic coupled lipid nanoparticles have potential application value in the fields of cancer treatment and the like.

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition combining an aquaporin inhibitor and amphotericin B for treating brain glioma, and the pharmaceutical composition comprises an AQP4 inhibitor AER-270 and amphotericin B. The invention further discloses a pharmaceutical preparation containing the pharmaceutical composition and application of the pharmaceutical preparation to preparation of drugs for treating brain glioma. The tumor cell inhibition effect of the pharmaceutical composition provided by the invention is obviously better than that of single AER270 or amphotericin B, the pharmaceutical composition has an obvious synergistic effect, and an effective drug combination strategy is provided for treatment of brain glioma.

This invention belongs to the field of regenerative medicine, specifically relating to a lacrimal gland organoid culture medium and a method for in vitro culture of lacrimal gland organoids. In one aspect, a lacrimal gland stem cell proliferation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, and Noggin; the lacrimal gland stem cell basal culture medium comprises: DMEM medium, F12 medium, L-glutamine, fetal bovine serum, hydrocortisone, cholera toxin, B27, penicillin, streptomycin, amphotericin B, and fasudil. In another aspect, a lacrimal gland stem cell differentiation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, Noggin, and BMP7. The lacrimal gland organoids constructed by this invention are larger in volume than those of existing technologies, possessing numerous branched ducts and vesicular acinar structures, extending radially and multidirectionally in a three-dimensional manner, forming a complex and regular three-dimensional tubular acinar network, and possessing secretory function.

The invention relates to the technical field of biological medicine, in particular to amphotericin B liposome and a preparation method thereof.The preparation method comprises the steps that S1, amphotericin B, a film-forming material, an antioxidant and an acidified organic solvent are evenly mixed and dried to obtain fat powder; s2, the fat powder is subjected to hydration, homogenization, filtration, incubation and freeze drying in sequence; the incubation temperature is 60 to 70 DEG C, and the incubation time is 2 to 12 hours. The liposome prepared by the method provided by the invention is a round small single-chamber liposome with a uniform form; through detection, the amphotericin B lipid compound has the compounding rate of more than or equal to 99%, the particle size is small, the average particle size is less than or equal to 100nm, the particle size after redissolving is 50-150nm, the toxicity is low (the potassium release value is high), and the amphotericin B lipid compound can be prepared into low-toxicity freeze-dried powder injection for injection.

The invention provides a preparation method of polyethylene glycol amphotericin B micelles, and belongs to the field of biological medicine manufacturing. The method comprises the following steps: reacting methoxy polyethylene glycol with lactide at 110-130 DEG C for 6-12 hours to obtain a block copolymer; the segmented copolymer and 2-(diisopropylamino) ethylamine are subjected to a reaction for 12-24 h, and a terpolymer is obtained; the terpolymer and 4-(hydroxymethyl) phenylboronic acid pinacol ester are subjected to a reaction for 12-36 h, and a quadripolymer is obtained; co-loading the quadripolymer and amphotericin B to obtain a micelle core; extracting a denucleated reticulated erythrocyte membrane from whole blood; and wrapping the outer surface of the micelle core with the denucleated reticulated erythrocyte membrane to obtain the polyethylene glycol amphotericin B micelle. Through the step-by-step design of intelligent response drug loading and bionic delivery camouflage, the dual purposes of'curative effect improvement and toxicity reduction 'of amphotericin B are achieved from three dimensions of accurate drug release, effective focus enrichment and normal tissue protection.

The MFSmt gene reveals the role of voriconazole in treating Aspergillus fumigatus under the condition of pathogenicity: the deletion of MFSmt gene leads to the increase of amphotericin B resistance and the increase of voriconazole sensitivity in Aspergillus fumigatus. This finding suggests that if the drug that makes the MFSmt gene deletion or reduces the amount of expressed protein is used in clinical treatment, it can be combined with voriconazole to have a more effective bactericidal effect, and at the same time, the use of amphotericin B should be avoided to prevent drug resistance. This has important clinical value for determining the treatment plan for effective treatment of clinical Aspergillus fumigatus infection and controlling drug-resistant strains.

The invention relates to application of a composition and application of farnesol in preparation of an aspergillus fumigatus resistant medicine, and belongs to the technical field of aspergillus fumigatus resistant medicines. The drug combination composition is prepared from farnesol and amphotericin B. The invention further discloses a preparation method of the drug combination composition. Farnesol is used as a synergist for resisting aspergillus fumigatus, the combined composition of farnesol and amphotericin B is obtained, and the minimum inhibitory concentration of amphotericin B for resisting aspergillus fumigatus can be synergistically reduced; farnesol and amphotericin B are combined for use, so that the growth of aspergillus fumigatus hyphae can be synergistically inhibited; farnesol and amphotericin B are combined for use, so that an aspergillus fumigatus biological membrane can be synergistically destroyed, and the defect of high toxicity caused by single use of amphotericin B in the background technology is overcome.

The invention discloses a stem cell serum-free culture process optimized by artificial intelligence, which comprises the following steps: isolated culture of hAMSCs: firstly taking a healthy cesarean delivery amnion, cleaning bloodstain, removing chorion, cutting, soaking in PBS for 20 minutes, taking out, cutting into pieces, adding 0.25% trypsin, digesting at 37 DEG C for 30 minutes, cleaning after stopping digestion, adding 1mg / mL type IV collagenase, digesting at 37 DEG C for 1 hour, and culturing for 2-3 hours; the method comprises the following steps: adding the human amniotic mesenchymal stem cells into a culture medium containing 10% of FBS, 10 ng / mL of bFGF, 10 ng / mL of LEGF, 100 U / mL of mycillin and 2.5 [mu] g / mL of amphotericin B, and carrying out conventional culture under the culture conditions of 37 DEG C, 5% of CO2 and saturated humidity. The method has the following advantages: compared with the human amniotic mesenchymal stem cells cultured by fetal calf serum, the migration ability of the human amniotic mesenchymal stem cells cultured by fetal calf serum is enhanced.